Treatment of hepatitis delta virus infection with interferon lambda
AssigneeEiger BioPharmaceuticals, Inc.
InventorsIngrid CHOONG, Eduardo Bruno MARTINS
Life of this patent
Estimating the term…
Abstract
Methods of treating a hepatitis delta virus (HDV) infection in a human subject are provided. In some embodiments, the method comprises subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a for at least 48 weeks.
Claims79
A method of treating a hepatitis delta virus (HDV) infection in a human subject, the method comprising subcutaneously administering to the subject a therapeutically effective amount of pegylated interferon lambda-1a until one or more of a sustained reduction of HDV viral load is reached or a decrease in HDV RNA to undetectable levels.
A method of treating a hepatitis delta virus (HDV) infection, comprising administering from about 80 to about 240 μg of pegylated interferon lambda-1a per week for at least four weeks, wherein between 1 day and 24 weeks post a last administration subjects have a durable virologic response (DVR).
The method of claim 69, wherein the subject exhibits an improvement in one or more liver function parameters, wherein the improved liver function is an improvement in one or more serum markers. 70. The method of claim 68, wherein the one or more liver function parameters include one or more of serum albumin, bilirubin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), prothrombin, alfa2-macroglobulin, apolipoprotein A1, haptoglobin, or gamma-glutamyl transpeptidase (GGT).
Dependencies are inferred from the claim text.